Cancer Exosomes Express CD39 and CD73, Which Suppress T Cells through Adenosine Production
Open accessThe DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Abstract
Extracellular adenosine is elevated in cancer tissue, and it negatively regulates local immune responses. Adenosine production from extracellular ATP has attracted attention as a mechanism of regulatory T cell-mediated immune regulation. In this study, we examined whether small vesicles secreted by cancer cells, called exosomes, contribute to extracellular adenosine production and hence modulate immune effector cells indirectly. We found exosomes from diverse cancer cell types exhibit potent ATP- and 5'AMP-phosphohydrolytic activity, partly attributed to exosomally expressed CD39 and CD73, respectively. Comparable levels of activity were seen with exosomes from pleural effusions of mesothelioma patients. In such fluids, exosomes accounted for 20% of the total ATP-hydrolytic activity. Exosomes can perform both hydrolytic steps sequentially to form adenosine from ATP. This exosome-generated adenosine can trigger a cAMP response in adenosine A(2A) receptor-positive but not A(2A) receptor-negative cells. Similarly, significantly elevated cAMP was also triggered in Jurkat cells by adding exosomes with ATP but not by adding exosomes or ATP alone. A proportion of healthy donor T cells constitutively express CD39 and/or CD73. Activation of T cells by CD3/CD28 cross-linking could be inhibited by exogenously added 5'AMP in a CD73-dependent manner. However, 5'AMP converted to adenosine by exosomes inhibits T cell activation independently of T cell CD73 expression. This T cell inhibition was mediated through the adenosine A(2A) receptor. In summary, the data highlight exosome enzymic activity in the production of extracellular adenosine, and this may play a contributory role in negative modulation of T cells in the tumor environment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Clayton et al. reported the expression of CD39, CD73, and eADO in MPM-derived exosome from pleural effusion, contributing to the inhibition of T cell functions [133].”
From Chronic Inflammation, Oxidative Stress and Metabolic Plasticity: Three Players Driving the Pro-Tumorigenic Microenvironment in Malignant Mesothelioma (2023) · cites this paper as [133]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Isolation and Characterization of Exosomes from Cell Culture Supernatants and Biological Fluids
Théry, C., Amigorena, S., Raposo, G., & Clayton, A. (2006) · Current Protocols in Cell Biology · doi:10.1002/0471143030.cb0322s30 · Cited by 5,766 · cited 1×
“To quantify the density of exosomes, we used a protocol similar to that previously described, based on ultracentrifugation on a linear sucrose gradient (36).”
MethodSelf-citationMembrane vesicles as conveyors of immune responses
Théry, C., Ostrowski, M., & Segura, E. (2009) · Nature Reviews Immunology · doi:10.1038/nri2567 · Cited by 3,882 · cited 1×
“immune-activating functions, there are also accumulating data pointing to varied suppressive effects (40).”
BackgroundB lymphocytes secrete antigen-presenting vesicles.
Raposo, G., Nijman, H. W., Stoorvogel, W., Liejendekker, R., Harding, C. V., Melief, C. J., & Geuze, H. J. (1996) · The Journal of experimental medicine · doi:10.1084/jem.183.3.1161 · Cited by 3,546 · cited 1×
“The density (g/ml) of each fraction was calculated from the published table in the Beckman Ultracentrifugation catalogue as described (37).”
MethodDeaglio, S., Dwyer, K. M., Gao, W., Friedman, D., Usheva, A., Erat, A., Chen, J.-F., Enjyoji, K., Linden, J., Oukka, M., et al. (2007) · The Journal of Experimental Medicine · doi:10.1084/jem.20062512 · Cited by 2,470 · cited 5×
“These are double-positive for CD39 and CD73 in mice (12) and according to one report also in human (45).”
BackgroundInfluentialOhta, A., & Sitkovsky, M. (2001) · Nature · doi:10.1038/414916a · Cited by 1,334
Borsellino, G., Kleinewietfeld, M., Di Mitri, D., Sternjak, A., Diamantini, A., Giometto, R., Höpner, S., Centonze, D., Bernardi, G., Dell'Acqua, M. L., et al. (2007) · Blood · doi:10.1182/blood-2006-12-064527 · Cited by 1,286 · cited 3×
“Natural regulatory T cells of mice express both CD39 and CD73, whose coordinated enzymatic actions produce adenosine as a mechanism for immune suppression that is independent of IL-10 and TGF-b (12, 13).”
BackgroundAdenosine receptors: therapeutic aspects for inflammatory and immune diseases
Haskó, G., Linden, J., Cronstein, B., & Pacher, P. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2638 · Cited by 1,217 · cited 1×
“mechanisms involved in adenosine formation and subsequent signaling are therefore of considerable therapeutic interest (9).”
BackgroundA2A adenosine receptor protects tumors from antitumor T cells
Ohta, A., Gorelik, E., Prasad, S. J., Ronchese, F., Lukashev, D., Wong, M. K. K., Huang, X., Caldwell, S., Liu, K., Smith, P., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0605251103 · Cited by 1,065 · cited 1×
“Adenosine also represses immune responses in the tumor microenvironment, assisting tumor immune evasion (7, 8).”
BackgroundMalignant effusions and immunogenic tumour-derived exosomes
Andre, F., Schartz, N. E., Movassagh, M., Flament, C., Pautier, P., Morice, P., Pomel, C., Lhomme, C., Escudier, B., Le Chevalier, T., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)09552-1 · Cited by 953 · cited 7×
“The cushion was collected and exosomes washed in PBS (32, 34, 35).”
MethodInfluentialExoCarta: A compendium of exosomal proteins and RNA
Mathivanan, S., & Simpson, R. J. (2009) · PROTEOMICS · doi:10.1002/pmic.200900351 · Cited by 873
Cited by
Items 401–500 of 564
Zhang, L., Wong, C. Y., & Shao, H. (2025) · Lab on a Chip · doi:10.1039/d5lc00053j · Cited by 9
Cheng, J., Zheng, J., Ma, C., Li, Y., & Hao, H. (2025) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2025.05.010 · Cited by 10
CD28 engagement inhibits CD73-mediated regulatory activity of CD8+ T cells
Lai, Y., Kuo, L.-C., Lin, B., Lin, H., Lin, C.-Y., Chen, Y., Hsiao, P., Chang, H., Ko, P. C., Chen, H.-C., et al. (2021) · Communications Biology · doi:10.1038/s42003-021-02119-9 · Cited by 9
Generation and characterization of antagonistic anti-human CD39 nanobodies
Menzel, S., Duan, Y., Hambach, J., Albrecht, B., Wendt, D., Winzer, R., Tolosa, E., Rissiek, A., Guse, A. H., Haag, F., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1328306 · Cited by 9
“CD39 can also occur in a non-cell-bound form, e.g. on tumor or regulatory T cell derived extracellular vesicles (24, 25) and by phosphodiesterase 3-induced shedding (26).”
BackgroundBranco, M. S. L. A., Cruz, A. G., Peri, L. E., & Mutafova–Yambolieva, V. N. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24129964 · Cited by 9
Moloudizargari, M., Asghari, M. H., & Mortaz, E. (2019) · DARU Journal of Pharmaceutical Sciences · doi:10.1007/s40199-019-00295-y · Cited by 9
“TEX can also promote the formation and function of regulatory T cells [14, 15], promote myeloid-derived suppressor cell (MDSC) differentiation [16], disturb the adhesive properties of leukocytes [17],”
BackgroundRana, R., Kant, R., Kaul, D., Sachdev, A., & Ganguly, N. K. (2022) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-021-04326-8 · Cited by 8
Reversal of Experimental Autoimmune Diabetes With an sCD39/Anti-CD3 Treatment
Fotino, C., Molano, R. D., Nasr, M. B., Umland, O., Fraker, C. A., Ulissi, U., Balasubramanian, H. B., Lunati, M. E., Usuelli, V., Seelam, A. J., et al. (2023) · Diabetes · doi:10.2337/db23-0178 · Cited by 9
Relevance of Splicing on Tumor-Released Exosome Landscape: Implications in Cancer Therapeutics
Oltra, E. (2014) · Frontiers in Endocrinology · doi:10.3389/fendo.2014.00194 · Cited by 8
“In addition, functional CD39 and CD73 Tex are capable of dephosphorylating ATP and AMP to form adenosine to negatively regulate local immune responses (20).”
Backgrounddo Carmo, T. I. T., Soares, V. E. M., Wruck, J., dos Anjos, F., Silva, D. T. D. R. E., Maciel, S. F. V. D. O., & Bagatini, M. D. (2021) · Inflammation Research · doi:10.1007/s00011-021-01464-z · Cited by 8
A Similarity-Based Method for Predicting Enzymatic Functions in Yeast Uncovers a New AMP Hydrolase
Cohen, N., Kahana, A., & Schuldiner, M. (2022) · Journal of Molecular Biology · doi:10.1016/j.jmb.2022.167478 · Cited by 8
The exploitation of enzyme-based cancer immunotherapy
Chandan, G., Saini, A. K., Kumari, R., Chakrabarti, S., Mittal, A., Sharma, A. K., & Saini, R. V. (2022) · Human Cell · doi:10.1007/s13577-022-00821-2 · Cited by 8
“Several antagonists of A2AR, such as NIR178/PBF-509, EOS100850, and AB928, are being analyzed for safety profile and effective outcomes for phase I/II trials [195].”
BackgroundInfluentialTrad, M., Gautheron, A., Fraszczak, J., Alizadeh, D., Larmonier, C. B., LaCasse, C. J., Centuori, S. M., Audia, S., Samson, M., Ciudad, M., et al. (2015) · BioMed Research International · doi:10.1155/2015/891236 · Cited by 8
“Recently, several groups have independently reported on the expression of CD39 by Treg, cancer exosomes, tumor cells, and multipotent mesenchymental stromal cells [30, 51, 52].”
BackgroundAdenosine Promotes Tumor Metastasis
Linden, J. M. (2013) · Science Signaling · doi:10.1126/scisignal.2004290 · Cited by 8
“Diverse cancer cell types exhibit potent ATP– adenosine diphosphate- and 5′–adenosine monophosphate (AMP)–phosphohydrolytic activities, which have been partly attributed to exosomal CD39 and CD73 that together increase extracellular adenosine production from adenine nucleotides (1).”
BackgroundGonzález, D. A., van Haaster, M. M. B., Villarruel, E. Q., Hattab, C., Ostuni, M. A., & Orman, B. E. (2019) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-019-03624-6 · Cited by 8
Park, H., Seo, E., Piao, L., Park, S.-T., Lee, M., Koh, S., Lee, S.-H., & Kim, S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22147478 · Cited by 8
Adenosine receptors on the immuno-oncology expressway: TIME, perspectives, and translation
Majumder, B., & Datta, S. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1676702 · Cited by 9
“Cancer-derived exosomes enriched in CD73 and CD39 suppress T-cell responses through complementary adenosinergic signaling (59).”
Adedokun, K. A., Bello, A., Oyeniyi, G. M., Oladejo, M., & Adebisi, T. A. (2026) · Clinical & Experimental Immunology · doi:10.1093/cei/uxag009 · Cited by 8
“The ectonucleotidases CD39 and CD73, which are expressed by Treg cells, are also pre-sent in their exosomes and catalyze the hydrolysis of ATP to adenosine, an immunosuppressive molecule that promotes M2 macrophage polarization and facilitates tissue repair [105, 106].”
Tripathi, S., Martín-Moreno, P. L., Kavalam, G., Schreiber, B., Waaga-Gasser, A. M., & Chandraker, A. K. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.849939 · Cited by 7
“ATP Hydrolysis Assay Extracellular ATP hydrolysis and production of adenosine by ASTRLs was determined by measuring the production of inorganic phosphate, a byproduct of the same reaction, using malachite green colorimetric assay kit from Anaspec according to the protocol of the manufacturer (14).”
MethodWang, B., Zhou, A., Pan, Q., Li, Y., Xi, Z., He, K., Li, D., Li, B., Liu, Y., Liu, Y., et al. (2023) · Translational research · doi:10.1016/j.trsl.2023.09.002 · Cited by 7
Role of exosomes and microvesicles in carcinogenesis
Никитина, И. Г., Sabirova, E. Y., Карпов, В. Л., Lisitsyn, N. A., & Beresten, S. F. (2013) · Molecular Biology · doi:10.1134/s0026893313050166 · Cited by 7
“pression consists in the local hydrolysis of ATP by CD39 and CD73 proteins located at the TEM surface, which results in the formation of adenosine that in turn suppresses functioning of the leukocytes, mac rophages, and lymphocytes that contain surface asso ciated receptors of adenosine (under normal condi tions, loca…”
Meyer, A. V., Klein, D., de Leve, S., Szymonowicz, K., Stuschke, M., Robson, S. C., Jendrossek, V., & Wirsdörfer, F. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.554883 · Cited by 7
Anzai, T., Saijou, S., Takashima, H., Hara, M., Hanaoka, S., Matsumura, Y., & Yasunaga, M. (2022) · Pharmaceuticals · doi:10.3390/ph15070837 · Cited by 7
Naaldijk, Y., Sherman, L. S., Turrini, N., Kenfack, Y., Ratajczak, M. Z., Souayah, N., Rameshwar, P., & Ulrich, H. (2023) · Stem Cell Reviews and Reports · doi:10.1007/s12015-023-10612-3 · Cited by 7
“Extracellular vesicles in modifying purinergic signaling have already been shown, such as the expression of NTPDase 1 (CD39) and CD73 in mesothelioma patient pleural fluid, which would hydrolyze extracellular ATP to AMP and AMP to adenosine, respectively [64].”
Exploring CD39 and CD73 Expression as Potential Biomarkers in Prostate Cancer
Gardani, C. F. F., Pedrazza, E. L., Paz, V. S., Zanirati, G., da Costa, J. C., Andrejew, R., Ulrich, H., Scholl, J. N., Figueiró, F., Rockenbach, L., et al. (2023) · Pharmaceuticals · doi:10.3390/ph16111619 · Cited by 7
“It is well established that tumor-cell-derived EVs that overexpress CD39 are also associated with the increased production of ADO, a potent immunosuppressive mediator [31].”
BackgroundBiomimetic and synthetic interfaces to tune immune responses (Review)
Garapaty, A., & Champion, J. A. (2015) · Biointerphases · doi:10.1116/1.4922798 · Cited by 9
Azparren‐Angulo, M., Royo, F., & Falcón‐Pérez, J. M. (2019) · Current Pathobiology Reports · doi:10.1007/s40139-019-00197-3 · Cited by 8
Iorio, P. D., & Ciccarelli, R. (2021) · Cells · doi:10.3390/cells10010188 · Cited by 9
“Of note, this last aspect has been mostly evaluated in tumors, in particular as concerns the activity/function of EVs, whose presence has been identified in the TME of different cancers [50,51], as discussed below and recently reviewed by Azambuja et al.”
BackgroundResultInfluentialPrognostic significance of NT5E/CD73 in neuroblastoma and its function in CSC stemness maintenance
Jain, D., Somasundaram, D. B., Aravindan, S., Yu, Z., Baker, A. A., Esmaeili, A., & Aravindan, N. (2021) · Cell Biology and Toxicology · doi:10.1007/s10565-021-09658-1 · Cited by 7
“The soluble form of CD73 is enzymatically more active than the membrane-bound variant (Lehto and Sharom 1998); in particular, CD73 in vesicles has been shown to maintain its enzymatic activity, and consequently, exosome-derived adenosine is responsible for T cell inhibition and impaired antitumor immune response (Clay…”
BackgroundControversies in therapeutic application of mesenchymal stem cell-derived secretome
Sípos, F., & Műzes, G. (2021) · Biocell · doi:10.32604/biocell.2022.018200 · Cited by 7
“, tumor-infiltrating T-cell function) via activation of adenosine receptor signaling present on the surface of most immune cells (Ohta and Sitkovsky, 2014; Clayton et al., 2011).”
BackgroundZhang, S., Chen, L., Zong, Y., Li, Q., Zhu, K., Li, Z., & Meng, R. (2022) · Cancer Medicine · doi:10.1002/cam4.5005 · Cited by 7
Dynamic recycling of extracellular ATP in human epithelial intestinal cells
Saffioti, N. A., Alvarez, C. L., Bazzi, Z., Gentilini, M. V., Gondolesi, G. E., Schwarzbaum, P. J., & Schachter, J. (2023) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1011196 · Cited by 7
“The intestinal cell line HT29 cells expressed functional ecto-NTPDase-2 displaying high ecto-ATPase activity [15], while Caco-2 cells and their exosomes were reported to exhibit ectoNTPDases-1 and -2 at the cell membrane [16,17].”
BackgroundCancer Immunotherapy—An Emerging Field That Bridges Oncology and Immunology Research
Adams, J. L., Duffy, K. J., Moore, M. L., & Yang, J. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-409547-2.12400-x · Cited by 9
Maralbashi, S., Aslan, C., Kahroba, H., Javadian, M., Shekari, N., Safarzadeh, E., Salari, F., & Kazemi, T. (2025) · Cancer Investigation · doi:10.1080/07357907.2025.2529878 · Cited by 8
Bottom‐Up Synthesis and Purification of Extracellular Vesicle Mimetics
van de Schepop, L., Stiemsma, Y. L., Wichers, L. X., Hotting, E. S., Smits, S. M., Seinen, C. W., Edelbacher, T. V., Barendrecht, A. D., van Wesel, A. C. W., Schiffelers, R. M., et al. (2025) · Journal of Extracellular Vesicles · doi:10.1002/jev2.70190 · Cited by 6
“CD39 has been detected on the surface of EVs from tumour cells and immune cells, including T cells (Schuler et al. 2014; Ludwig et al. 2020; Clayton et al. 2011).”
Exosomes in tissue engineering and cell-free therapy: A comprehensive review
Zhang, L., Yang, F. F., Liu, J. B., Li, M., Mao, F., Ocansey, D. K. W., & Wu, Y. B. (2026) · European Cells and Materials · doi:10.22203/ecm.v055a06 · Cited by 7
“This intriguing mechanism is also utilized by exosomes derived from cancer cells [91] and Tregs [82], highlighting the complex interplay in immune regulation.”
Hong, C., Menshikova, E. V., Whiteside, T. L., & Jackson, E. K. (2024) · Purinergic Signalling · doi:10.1007/s11302-024-10038-7 · Cited by 6
“Among various immunosuppressive molecular pathways utilized by TEX, the adenosinergic pathway is emerging as a major contributor to TEX-induced suppression of immune cells and a promoter of tumor growth and metastasis [20, 21].”
Hussain, M., Javeed, A., Ashraf, M., Hou, Y., & Mukhtar, M. M. (2013) · Pharmacological Research · doi:10.1016/j.phrs.2013.04.006 · Cited by 9
Coban, B., Wang, Z., Liao, C., Beslmüller, K., Timmermans, M. A. M., Martens, J. W. M., Hundscheid, J. H. M., Slütter, B., Zweemer, A. J. M., Neubert, E., et al. (2024) · iScience · doi:10.1016/j.isci.2024.109738 · Cited by 6
“59 Our study demonstrates that GRHL2 levels can contribute to modulation of adenosine production by tumor cells, but further ( in vivo ) work is required to reveal the relative contribution of adenosine produced by GRHL2-negative tumor cells in such a complex environment.”
Characterization and Fine Structure of Exosomes
Alshubaily, F. A., & Al-Zahrani, M. H. (2020) · Springer eBooks · doi:10.1007/978-981-15-6599-1_2 · Cited by 8
Wang, X., Zhang, L., Du, J., Wei, Y., Wang, D., Song, C., Chen, D., Li, B., Jiang, M., Zhang, M., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.869286 · Cited by 8
“Age (mean, years) 34 ± 7 32 ± 10 31 ± 7 35 ± 8 36 ± 6 39 ± 7 CD4 count (cells/mm(3)), median (IQR) – 456 (408-529) 281 (244-312) 83 (33-146) 628 (560-743) 271 (229-328) CD8 count (cells/mm(3)), median (IQR) – 1085 (796-1401) 1017 (727-1267) 729 (547-904) 788 (656-1009) 691 (600-790)”
Molina-Castillo, G., Monroy-García, A., García‐Rocha, R., Weiss‐Steider, B., Montesinos, J. J., Hernández‐Montes, J., Don‐López, C. A., Castro-Manrreza, M. E., Escobar, M. L., & Mora‐García, M. D. L. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26062413 · Cited by 5
“The secretion of EVs by different types of cells, including tumor cells, can induce the formation of an immunosuppressive microenvironment through the generation of Ado [18].”
Impact of Immune Cells on IgA Vasculitis via Metabolites and Inflammatory Cytokines
Xie, M., Zhou, N., Liang, Q., Zhong, L., & Yao, Y. (2025) · Journal of Clinical Immunology · doi:10.1007/s10875-025-01946-3 · Cited by 5
“CD39 is constitutively expressed in regulatory T cells (Tregs) [33 ].”
QADEER, A., Ullah, A., Khan, M. Z., Alsharif, K. F., Alzahrani, F. M., Alzahrani, K. J., & Abuderman, A. (2026) · Metabolites · doi:10.3390/metabo16030207 · Cited by 5
G protein-coupled receptors: a gateway to targeting oncogenic EVs?
Niro, L. D., Linders, A. C., Glynn, T., Pegtel, D. M., Siderius, M. H., Crudden, C., & Smit, M. J. (2024) · Extracellular Vesicles and Circulating Nucleic Acids · doi:10.20517/evcna.2024.10 · Cited by 5
Duret, T., Elmallah, M. I. Y., Rollin, J., Gatault, P., Jiang, L., & Roger, S. (2024) · Biomedical Journal · doi:10.1016/j.bj.2024.100805 · Cited by 5
“Clayton et al. reported the generation of adenosine by exosome CD39 and CD73 from several human cancer cell lines and the resulting inhibition of T cells through activation of the A2A adenosine receptor [123].”
[Blocking Adenosine/A2AR Pathway for Cancer Therapy].
Liu, J., Shi, Y., Liu, X., Zhang, D., Bai, Y., Xu, Y., & Wang, M. (2022) · PubMed Central · doi:10.3779/j.issn.1009-3419.2022.102.24 · Cited by 7
Coray, M., Göldi, V., Schmid, L., Benecke, L., Figueiró, F., & Müller, L. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232214446 · Cited by 5
“Intriguingly, exosomes also carry and release CD39 and CD73, which play a major role in immunosuppression [25,27,31,32,36,37].”
BackgroundZhou, Q., Li, Z., & Xi, Y. (2024) · Experimental Hematology · doi:10.1016/j.exphem.2024.104175 · Cited by 6
Peters, M., Halvaei, S., Zhao, T., Yang-Schulz, A., Williams, K. C., & Gordon, R. (2024) · Journal of Physics Photonics · doi:10.1088/2515-7647/ad5776 · Cited by 5
Lin, W., Lin, Y., Chao, H., Lin, Y., & Hwang, W. (2023) · Clinical and Translational Medicine · doi:10.1002/ctm2.1448 · Cited by 5
Participation of local exosomes of acupoints in the initiation of acupuncture analgesic effect
Chen, B., Li, M., Li-ying, X. I. N. G., Zhuo, X.-M., Chen, Z., Guo, Y., & Li, M. (2018) · 世界针灸杂志:英文版 · doi:10.1016/j.wjam.2019.01.001 · Cited by 4
Schweiger, M. W., & Tannous, B. A. (2020) · Advanced Biosystems · doi:10.1002/adbi.202000035 · Cited by 4
Purinergic Receptors: Novel Targets for Cancer Immunotherapy
Vijayan, D., Smyth, M. J., & Teng, M. W. L. (2017) · Springer eBooks · doi:10.1007/978-3-319-62431-0_7 · Cited by 5
Extracellular Vesicles as Innovative Tools for Assessing Adverse Effects of Immunosuppressant Drugs
Lucafò, M., Biasi, S. D., Curci, D., Norbedo, A., Stocco, G., & Decorti, G. (2021) · Current Medicinal Chemistry · doi:10.2174/0929867328666211208114022 · Cited by 4
Dai, S., Liu, T., He, Y., Huang, Y., Wang, L., Luo, F., & Li, Y. (2022) · Heliyon · doi:10.1016/j.heliyon.2022.e12108 · Cited by 4
“CD73 is a major nucleoti de-metabolizing enzyme expressed in the TME and various cells such as immune cells, mesenchymal stem cells, and epithelial cells [20, 21, 22].”
BackgroundAdenosine A2A Receptor Antagonists: Chemistry, SARs, and Therapeutic Potential
Spinaci, A., Buccioni, M., Cui, C., Ben, D. D., Francucci, B., Lambertucci, C., Volpini, R., & Marucci, G. (2023) · Topics in medicinal chemistry · doi:10.1007/7355_2023_162 · Cited by 5
Ectonucleotidases in Cancer and Inflammation
Stagg, J., Thompson, L. F., & Dwyer, K. M. (2012) · BioMed Research International · doi:10.1155/2012/951423 · Cited by 5
Wang, P., He, Q., Xu, Y., Chen, Y., Zeng, X., Deng, K., & Xie, Q. (2026) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2026.119268 · Cited by 3
Adenosine as a metabolic checkpoint in CD8+ T cell dysfunction
Edgerton, A. O., Reginato, M. J., Kutzler, M. A., & Haddad, E. K. (2026) · Trends in Immunology · doi:10.1016/j.it.2026.06.005 · Cited by 4
Immuntherapie von Kopf-Hals-Karzinomen: Aktuelle Entwicklungen
Schuler, P. J., Hoffmann, T. K., Gauler, T. C., Bergmann, C., Brandau, S., & Lang, S. (2012) · HNO · doi:10.1007/s00106-012-2635-6 · Cited by 4
Enzyme activity of circulating CD73 in human serum
Morello, S., Turiello, R., Madonna, G., Pinto, A., Ascierto, P. A., & Capone, M. (2019) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/bs.mie.2019.05.044 · Cited by 3
CD73 promotes the maturation of murine NK cells and their survival in the tumor microenvironment
Parra-Tello, B., García-Gómez, M., Rekus-Polanska, E., Malgue, F., Charlín, S., Hernández‐Oliveras, A., Reyes-Alvarez, J., Rosemblatt, M. S., Lundqvist, A., Lladser, Á., et al. (2025) · Journal of Leukocyte Biology · doi:10.1093/jleuko/qiaf011 · Cited by 3
Halvaei, S., Salmond, N., & Williams, K. C. (2025) · Nanoscale · doi:10.1039/d4nr02510e · Cited by 3
Wen, J., Zhang, H., Meng, C., Zhou, D., Chen, G., Wang, J., Liu, Y., Yuan, L., & Li, N. (2022) · Structural Chemistry · doi:10.1007/s11224-021-01863-2 · Cited by 3
“CD73 is a surface enzyme anchored outside the cell membrane by glycosylphosphatidylinositol (GPI), it can convert AMP into adenosine and expressed in cancer cells, DC cells, Treg (regulatory T cells), NK cells [6, 7].”
BackgroundCD39+ tumor infiltrating T cells from colorectal cancers exhibit dysfunctional phenotype
Feng, Y. (2024) · American Journal of Cancer Research · doi:10.62347/izen3736 · Cited by 3
“Of note, the immunosuppressive role of CD39 and CD73 has been reported in myeloid cells, cancer cells, and even cancer exosomes, which generated extracellular adenosine and suppressed T-cell functions [30, 31].”
BackgroundWhiteside, T. L., Sehra, S., Chadderton, T., Guha, M., Stubbs, M. C., Timmers, C. D., & Jackson, E. K. (2025) · Immuno-Oncology Technology · doi:10.1016/j.iotech.2025.101052 · Cited by 3
“13 14-16 Thus, TEX have emerged as a major source of immunosuppressive exogenous ADO which mediates pro-tumor activities in cancer patients.”
A Snapshot of the Tumor Microenvironment in Colorectal Cancer: The Liquid Biopsy
Herrera, M., Galindo-Pumariño, C., García‐Barberán, V., & Peña, C. (2020) · Vide Leaf, Hyderabad eBooks · doi:10.37247/pamb.1.2020.9 · Cited by 3
Botbol, Y. M., Alves, V., Nimrichter, L., Macián, F., Nosanchuk, J. D., & Zamith‐Miranda, D. (2025) · The Journal of Immunology · doi:10.1093/jimmun/vkaf302 · Cited by 2
Aden, D., Zaheer, S., & Zaheer, S. (2026) · Cell Biology International · doi:10.1002/cbin.70156 · Cited by 2
“Adenosine is a potent immunosuppressive metabolite produced by TAMs in the TME, particularly under hypoxic conditions where there is an increased breakdown of ATP into adenosine (Pilon‐Thomas et al. 2016; Xing et al. 2023; Clayton et al. 2011).”
Liu, W., Xu, W., Liu, W., Liang, R., Tang, S., Luo, X., Liu, C., Liao, Q., Sun, H., Wang, Z., et al. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1738966 · Cited by 4
“Exosomes displaying FasL directly trigger apoptosis in CD8 + T cells (198).”
Role of Mesenchymal Stem Cells—Derived Exosomes in Osteoarthritis Treatment
Huňáková, K., Hluchý, M., Kuricová, M., Ševčík, K., Rosocha, J., & Ledecký, V. (2018) · Folia veterinaria · doi:10.2478/fv-2018-0033 · Cited by 2
“The presence of exosomes in: various physiological fluid/human blood [3], human urine [3, 26], bronchial lavage fluids [1] and the large diversity in exosome – secreting cell types/B cells [28], dendritic cells [45] mast cells [29], T cells [25], platelets [11], Schwann cells [9], tumour cells [37], mesenchymal stem c…”
BackgroundPurinergic Signaling in Brain Tumors
Bento, C. A., Guimarães, L. M. F., Arnaud-Sampaio, V. F., Rabelo, I. L. A., Juvenal, G. D. A., Ulrich, H., & Lameu, C. (2023) · Springer eBooks · doi:10.1007/978-3-031-26945-5_13 · Cited by 2
Ectoenzymes in Epithelial Ovarian Carcinoma: Potential Diagnostic Markers and Therapeutic Targets
Lo, N., Morone, S., Parrotta, R., Giacomino, A., Ortolan, E., & Funaro, A. (2012) · InTech eBooks · doi:10.5772/28428 · Cited by 2
“adenosine levels within the tumour microenvironment and hence participate to the negative regulation of T cell function (Clayton et al., 2011).”
BackgroundCRITICAL ASSESSMENT OF VIRTUAL SCREENING FOR HIT IDENTIFICATION
Stumpfe, D., & Bajorath, J. (2013) · Wiley eBooks · doi:10.1002/9781118742785.ch6 · Cited by 2
Role of Extracellular Vesicles in Cancer Pathogenesis
Elewaily, M. I. (2022) · Springer eBooks · doi:10.1007/978-3-030-80962-1_42-1 · Cited by 1
Purinergic ecto-enzyme CD73 is a context-dependent tumor suppressor in colorectal cancer
Chau, T. L., Borucu, Ü., Uygur, B., Özkurt, A. G., Kılıç, E., Işık, A., Gemalmayan, A. D., Cekic, C., Akyol, A., Canlı, S. D., et al. (2025) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2025.110864 · Cited by 1
Cao, X., Peng, Y., Liu, S., Zhou, C., Gao, L., Xiong, J., Zhou, M., Xia, M., & Xiong, Y. (2025) · Molecular Biology Reports · doi:10.1007/s11033-025-11265-w · Cited by 1
Tripathi, S., Julé, A. M., Zhu, Z., Schreiber, B., Martín-Moreno, P. L., Sui, S. H., Waaga-Gasser, A. M., & Chandraker, A. K. (2026) · Scientific Reports · doi:10.1038/s41598-025-33656-6 · Cited by 1
Tavasolian, F., Ravarian, B., Lim, M., & Inman, R. D. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1738120 · Cited by 1
“Achieving bene fi t will require precise control of exosomal cargo and tissue targeting to con fi ne activity to immune compartments while avoiding stromal activation (73, 85, 86).”
Li, S., Zhang, Y., Zhang, T., Wang, J., & Sun, J. (2026) · Fish & Shellfish Immunology · doi:10.1016/j.fsi.2026.111293 · Cited by 1
Fu, Z., Kuang, Y., Li, M., Zhou, K., Shi, H., Gu, Y., Wu, X., Zhu, Y., & Liu, J. (2026) · Extracellular Vesicles and Circulating Nucleic Acids · doi:10.20517/evcna.2025.184 · Cited by 1
Immunotherapy in pancreatic cancer: overcoming the challenges of tumor heterogeneity
Nakamura, M., He, Z., Dhulia, R., Manji, G. A., & Reya, T. (2026) · Trends Open · doi:10.1016/j.treopn.2026.04.001 · Cited by 1
Bertolucci, R. V., Klein, B., Pase, C. C., de Melo, V. C., & Bagatini, M. D. (2026) · Pharmaceuticals · doi:10.3390/ph19060913 · Cited by 1
“Integrative transcriptomic and functional data suggest that CD73 inhibition may reprogram this refractory state, potentially converting nonresponsive tumors into those sensitive to immunotherapy [16,94].”
Nabe, Y., Fujita, Y., Hashimoto, T., Tanaka, K., Manabe, T., Yoshimatsu, K., Nemoto, Y., Nishizawa, N., Oyama, R., HONDA, Y., et al. (2026) · In Vivo · doi:10.21873/invivo.14373 · Cited by 1
Nguyen, T. V., & Hsu, T. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27136021 · Cited by 1
“Interestingly, Clayton et al. discovered that exosomes isolated from mesothelioma patients express CD73 and CD39 [104].”
Immune Modulation of T Cells and Natural Killer Cells by Tumor-Derived Exosomes
Whiteside, T. L. (2012) · Springer eBooks · doi:10.1007/978-1-4614-3697-3_7 · Cited by 2
Endometrial Regenerative Cells and Exosomes Thereof for Treatment of Radiation Exposure
Bogin, V., & Ichim, T. E. (2014) · Springer eBooks · doi:10.1007/978-1-4471-6542-2_4 · Cited by 1
Tumor Exosomes and Their Impact on Immunity and Cancer Progression
Huber, V., Filipazzi, P., & Rivoltini, L. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-394296-8.00030-0 · Cited by 2
Overview of Extracellular Vesicles in Health and Disease
Nieuwland, R., van der Pol, E., & Sturk, A. (2014) · Pan Stanford Publishing eBooks · doi:10.1201/b15647-2 · Cited by 1
Exosomes in Cancer Immunotherapy
Takahashi, Y., & Takakura, Y. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-812774-2.00017-1 · Cited by 1
Endogenous Radionanomedicine: Extracellular Vesicles
Lee, C., Hwang, D. W., & Gho, Y. S. (2018) · Biological and medical physics, biomedical engineering · doi:10.1007/978-3-319-67720-0_6 · Cited by 1
Exosomes, PD-L1 and aGvHD: Perspectives for WJMSCmediated Therapy
Li, M., Abdelhakim, H., Braun, M. W., & Godwin, A. K. (2021) · Journal of Cancer Immunology · doi:10.33696/cancerimmunol.3.044 · Cited by 1
“reported that MSC EVs reduced the proinflammatory cytokine response of patient’s PBMCs and the clinical GvHD symptoms during the course of MSC EVs therapy [28].”
BackgroundThe Effect of the Tumor Microenvironment and Tumor-Derived Metabolites on Dendritic Cell Function
Lee, J., Choi, S., Jung, N.-C., & Lim, D. (2020) · Vide Leaf, Hyderabad eBooks · doi:10.37247/pacr.1.2020.26 · Cited by 1
Biogenesis of extracellular vesicles and their role in cancer
Sharma, S., Singh, A. N., & Rana, R. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-95258-3.00004-7 · Cited by 1
Isolation and Characterization of Cancer-Derived Exosomes
Pavlova, G. D. (2016) · NORA - Norwegian Open Research Archives · Cited by 2
Céspedes, P. F., Jainarayanan, A., Fernández‐Messina, L., Saliba, D. G., Valvo, S., Kvalvaag, A. S., Chen, L., Kurz, E., Ganskow, C. S. G., Colin‐York, H., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.05.29.445691 · Cited by 1
“The inclusion of itinerant enzymes such as CD38, CD39 and CD73 in SV, although limited, might exert a feed-forward regulatory effect as shown for tumor-derived exosomes[31].”
BackgroundMaia, J. (2021) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) · doi:10.34626/ee2z-xh38 · Cited by 1
Prospects for the Induction of Transplant Tolerance Using Dendritic Cells
Buckland, M. S., Smyth, L. A., Lechler, R. I., & Lombardi, G. (2012) · Springer eBooks · doi:10.1007/978-1-4614-5480-9_13
“Exosomes derived from cancer cells expressing CD73 and CD39 have been shown to directly suppress T cell function [147].”
BackgroundCombination of Immunotherapy & Radiotherapy for the Treatment of Prostate Cancer
Tabi, Z., Lisa, K. M., & Staffurth, J. N. (2011) · InTech eBooks · doi:10.5772/27790 · Cited by 1
Self-citation
Metadata
- Authors
- Clayton, A., Al-Taei, S., Webber, J., Mason, M. D., & Tabi, Z.
- Affiliations
- Velindre Cancer Centre (GB)
- Department of Pharmacology, Radiology and Oncology, School of Medicine, Cardiff University, Velindre Cancer Centre , Whitchurch, Cardiff CF14 2TL ,
- Corresponding author
- Clayton, Aled
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 2011-07
- Volume
- 187
- Issue
- 2
- Pages
- 676-683
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- OpenAlex
- W2153092839
- Cited by
- 540
- References
- 49
- Citations by year
- 2026: 18 · 2025: 30 · 2024: 31 · 2023: 38 · 2022: 53 · 2021: 50 · 2020: 61 · 2019: 37 · 2018: 36 · 2017: 29 · 2016: 30 · 2015: 24 · 2014: 33 · 2013: 26 · 2012: 40
- FWCI
- 23.02
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- The Journal of Immunology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Physiology › Adenosine and Purinergic Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Extracellular vesicles in disease
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Biochemical and Molecular Research
- Keywords
- tumor-derived exosomes, CD39, CD73, extracellular adenosine, ATP hydrolysis, 5'-AMP, adenosine A2A receptor, cAMP signaling, T cell activation inhibition, tumor immunosuppression, mesothelioma, extracellular vesicles
- MeSH terms
- Adenosine, Adenosine Monophosphate, Adenosine Triphosphate, Apyrase, Humans, Hydrolysis, Mesothelioma, Phosphorylation, Pleural Neoplasms, Down-Regulation, Antigens, CD, 5'-Nucleotidase, Caco-2 Cells, Jurkat Cells, Cell Line, Tumor, T-Lymphocytes, Regulatory, Exosomes, GPI-Linked Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.